SCHEMBL6722065

SCHEMBL6722065

Cc1cccc(-c2cccnc2-c2ccc(S(N)(=O)=O)c(F)c2)c1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.43
PTGS1 P23219 3/20 0.43
FEN1 P39748 8/20 0.42
ALOX5AP P20292 7/20 0.42
PTGES2 Q9H7Z7 1/20 0.40
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
LRRK2 Q5S007 1/20 0.39
KMO O15229 1/20 0.39
RPS6KA3 P51812 1/20 0.39
TGFBR1 P36897 1/20 0.38
F2 P00734 1/20 0.38
F10 P00742 1/20 0.38
PRSS1 P07477 1/20 0.38
PRSS2 P07478 1/20 0.38
PRSS3 P35030 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6730452 0.91 PTGS2 (0.45) PTGS2PTGS1FEN1ALOX5APCA1
SCHEMBL7537439 0.89 PTGS2 (0.48) PTGS2PTGS1FEN1ALOX5APKMO
SCHEMBL6718407 0.89 PTGS2 (0.47) PTGS2PTGS1FEN1ALOX5APCA1
SCHEMBL6718427 0.88 FEN1 (0.46) PTGS2PTGS1FEN1ALOX5APPTGES2
SCHEMBL6725390 0.88 PTGS2 (0.45) PTGS2PTGS1FEN1ALOX5APCA1
SCHEMBL6729554 0.87 PTGS2 (0.48) PTGS2PTGS1FEN1ALOX5APKMO
SCHEMBL6725930 0.87 PTGS2 (0.48) PTGS2PTGS1FEN1ALOX5APCA1
SCHEMBL6718496 0.87 PTGS2 (0.52) PTGS2PTGS1FEN1ALOX5APCA1
SCHEMBL6723580 0.87 ALOX5AP (0.48) PTGS2PTGS1FEN1ALOX5APCA1
SCHEMBL6728769 0.87 FEN1 (0.46) PTGS2PTGS1FEN1ALOX5APCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-05-13 US disclosed
EP-1296971-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2003-04-02 EP disclosed
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2002-12-05 US disclosed
WO-2001081332-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, FPR1, PTGES2 PTGS2 5/4885PTGS1 4/4885FEN1 1649/4885
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, PTGES2, FPR1 PTGS2 5/4885PTGS1 4/4885FEN1 1713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.